Therapeutic effects of methotrexate encapsulated in hyaluronic acid-coated exosomes derived from Wharton's jelly mesenchymal stem cells in a rat model of rheumatoid arthritis

Key Points

• Methotrexate encapsulated in exosomes significantly reduces inflammation in the rat model of rheumatoid arthritis.
• Treatment led to a 40% decrease in joint swelling within two weeks, indicating strong therapeutic potential.
• Employing exosomes from Wharton's jelly mesenchymal stem cells allowed targeted delivery of the drug.
• This approach may enable future advances in rheumatoid arthritis treatment strategies.